Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetyl-CoA carboxylase 1 and Acetyl-CoA carboxylase 2 are large, multi-domain, biotin-dependent enzymes that catalyze the carboxylation of acetyl-CoA to form malonyl-CoA, the first and regulatory step in fatty acid synthesis. ACC1 is predominantly cytosolic and controls de novo fatty acid biosynthesis, while ACC2 is associated with mitochondria and regulates fatty acid oxidation by producing malonyl-CoA that inhibits carnitine palmitoyltransferase 1. Both are tightly regulated by phosphorylation (notably by AMPK), polymerization, and allosteric modulators, making them attractive and validated therapeutic targets in cancer, metabolic disease, and cardiovascular conditions.
Inhibition of ACC1/ACC2 reduces malonyl-CoA production, suppressing de novo fatty acid synthesis. ACC2 inhibition increases mitochondrial fatty acid oxidation by reducing malonyl-CoA inhibition of carnitine palmitoyltransferase 1. Modulation of ACC dimerization and phosphorylation status controls enzymatic activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetyl-CoA carboxylase 1 and Acetyl-CoA carboxylase 2 (ACC1 and ACC2).